The Clinical Efficacy of the Regeneten Bioinductive Implant in Rotator Cuff Repair: A Systematic Review.

IF 0.5 4区 医学 Q4 ORTHOPEDICS
Marouane Benthami Kbibi, Filip Verhaegen, Philippe Debeer
{"title":"The Clinical Efficacy of the Regeneten Bioinductive Implant in Rotator Cuff Repair: A Systematic Review.","authors":"Marouane Benthami Kbibi, Filip Verhaegen, Philippe Debeer","doi":"10.52628/90.4.13834","DOIUrl":null,"url":null,"abstract":"<p><p>Despite advancements in surgical techniques for rotator cuff repair, retear rates remain a significant concern. This study systematically reviews the evidence on the effectiveness of the Regeneten Bioinductive Implant in improving healing outcomes. A systematic review of the literature was conducted by searching on PubMed, Embase, Web of Science Core Collection and Cochrane Library. Studies reporting on effectiveness, safety, radiological, clinical outcomes, or patient- reported outcomes after Regeneten use, with at least 12 months of follow-up, were considered. 17 articles were included in this review, encompassing data on 1062 rotator cuff tears, of which 966 were treated with Regeneten. The implant use resulted in retear rates of 0% up to 18% after 5 years in PT tears and 0% up to 35% after 2 years in FT tears. In 1 randomised trial, the retear rate was significantly lower in the implant group compared to the control group. Constant- Murley Score (CMS) and the American Shoulder and Elbow Surgeons (ASES) score showed a sustained improvement compared to pre-operative scores across all studies. MRI showed increased tendon thickness starting from 6 months, with MRI signals suggesting that the implant was integrating with the native tendon and becoming indistinguishable. While using Regeneten for rotator cuff tears of various sizes and chronicity is associated with reduced retear rates in some studies, the clinical outcomes remain within the same range as those seen with traditional rotator cuff repair. Additional randomized controlled trials are required to validate these results and clarify the appropriate indications for using this implant.</p>","PeriodicalId":7018,"journal":{"name":"Acta orthopaedica Belgica","volume":"90 4","pages":"777-788"},"PeriodicalIF":0.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta orthopaedica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.52628/90.4.13834","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Despite advancements in surgical techniques for rotator cuff repair, retear rates remain a significant concern. This study systematically reviews the evidence on the effectiveness of the Regeneten Bioinductive Implant in improving healing outcomes. A systematic review of the literature was conducted by searching on PubMed, Embase, Web of Science Core Collection and Cochrane Library. Studies reporting on effectiveness, safety, radiological, clinical outcomes, or patient- reported outcomes after Regeneten use, with at least 12 months of follow-up, were considered. 17 articles were included in this review, encompassing data on 1062 rotator cuff tears, of which 966 were treated with Regeneten. The implant use resulted in retear rates of 0% up to 18% after 5 years in PT tears and 0% up to 35% after 2 years in FT tears. In 1 randomised trial, the retear rate was significantly lower in the implant group compared to the control group. Constant- Murley Score (CMS) and the American Shoulder and Elbow Surgeons (ASES) score showed a sustained improvement compared to pre-operative scores across all studies. MRI showed increased tendon thickness starting from 6 months, with MRI signals suggesting that the implant was integrating with the native tendon and becoming indistinguishable. While using Regeneten for rotator cuff tears of various sizes and chronicity is associated with reduced retear rates in some studies, the clinical outcomes remain within the same range as those seen with traditional rotator cuff repair. Additional randomized controlled trials are required to validate these results and clarify the appropriate indications for using this implant.

Regeneten生物诱导植入物在肩袖修复中的临床疗效:系统综述。
尽管肩袖修复的手术技术有所进步,但再撕裂率仍然是一个值得关注的问题。本研究系统地回顾了Regeneten生物诱导植入物在改善愈合效果方面的有效性证据。通过检索PubMed、Embase、Web of Science Core Collection和Cochrane Library对文献进行系统综述。研究报告了Regeneten使用后的有效性、安全性、放射学、临床结果或患者报告的结果,至少随访12个月。本综述纳入了17篇文章,包括1062例肩袖撕裂的数据,其中966例使用Regeneten治疗。植入物的使用导致PT撕裂5年后的再撕裂率为0% - 18%,FT撕裂2年后的再撕裂率为0% - 35%。在1个随机试验中,种植体组的恢复率明显低于对照组。在所有研究中,Constant- Murley评分(CMS)和American Shoulder and肘部外科医生(ASES)评分与术前评分相比持续改善。MRI显示从6个月开始肌腱厚度增加,MRI信号提示植入物与原有肌腱融合,变得难以区分。虽然在一些研究中,使用Regeneten治疗不同大小和慢性的肩袖撕裂可降低撕裂率,但临床结果与传统的肩袖修复术保持在相同的范围内。需要额外的随机对照试验来验证这些结果,并明确使用该植入物的适当适应症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta orthopaedica Belgica
Acta orthopaedica Belgica 医学-整形外科
CiteScore
0.70
自引率
0.00%
发文量
58
审稿时长
4-8 weeks
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信